ArticleJournal of clinical laboratory analysis2026
Ginsenoside Rb1 Targets the HRD1-STING Axis to Mitigate Cholesterol-Induced VSMC Senescence.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundVascular smooth muscle cells (VSMCs) are crucial components of the arterial wall, playing a vital role in maintaining vascular integrity and function. Previous studies have identified HRD1 as a potential target for alleviating senescence in VSMCs. Ginsenoside Rb1 has been shown to counteract endothelial cell senescence triggered by H
methodsIn this study, Rb1 was investigated to determine if it could protect VSMCs from cholesterol-induced senescence. VSMCs were pretreated with Rb1 and subsequently exposed to cholesterol to evaluate its effects on SA-β-gal activity, reactive oxygen species (ROS) generation, cell viability, and STING pathway activation.
resultsRb1 treatment significantly reduced the proportion of SA-β-gal-positive cells induced by cholesterol. Moreover, Rb1 suppressed the activation of endoplasmic reticulum (ER) stress markers and inhibited STING signaling. HRD1 knockdown abrogated the Rb1-mediated reduction of ROS production. Similarly, both Rb1 and an STING inhibitor decreased cholesterol-induced mitochondrial ROS (MitoSOX) levels.
conclusionThese findings indicate that Rb1 protects VSMCs against cholesterol-induced senescence by preserving HRD1 expression, mitigating ER stress, and maintaining mitochondrial function. Therefore, Rb1 holds therapeutic potential for preventing vascular diseases associated with VSMC senescence by modulating the HRD1 and STING pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.